Bob Jackson trained as a pharmacologist, earning a Ph.D. from Institute of Cancer Research, London and Surrey. Following postdoctoral work at Yale University and Scripps Clinic, he held academic positions at the Institute of Cancer Research and Indiana University. Industry positions included Director of Chemotherapy at Warner-Lambert/Parke Davis and Group Director, Cancer Research, at Du Pont. He held the position of Head of R&D at four biotech companies (Agouron, Chiroscience, Celltech-Chiroscience, Cyclacel). In total, he managed the development of 25 drugs into clinical trials, five of which are currently marketed. He is sole author of two books, and author or co-author of over 170 other publications. He has been member and chair of several study sections and other advisory committees for NCI, NIH, the UK government and the European Union. He is currently the chairman of the Discovery Committee of Cancer UK.